Terazocin HCl (63074-08-8) is an α1- and α2B-adrenoceptor antagonist (K_i = 3.3, 0.7, 1.1, 7.7, 1510 and 78.2 nM for α1A, α1B, α1D, α2B, α2A and α2C receptors respectively)¹. Displays antihypertensive activity². Improves glucose and lipid metabolism in hypertensives³. Displays antiangiogenic activity in human prostate cancer and endothelial cells⁴. Terazocin activates Pgk1 and Hsp90 to promote stress resistance⁵. Active in vivo.

References/Citations
1) Hancock et al. (1995), Actions of terazosin and its enantiomers at subtypes of alpha-1 and alpha-2 adrenoceptors in vitro; Recept. Signal Transduct. Res., 15 863
2) Kyncl et al. (1986), Pharmacology of terazosin; Am. J. Med., 80 12
3) Shionoiri et al. (1994), Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: a multicenter prospective study; Am. J. Med. Sci., 307 Suppl 1 S91
4) Pan et al. (2003), Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells; J. Urol., 169 724
5) Chen et al. (2015), Terazosin activates Pgk1 and HSP90 tp promote stress resistance; Nat. Chem. Biol., 11 19